A microbe-made molecule may reverse gut damage by boosting NAD levels
· Medical Xpressedited by Gaby Clark, reviewed by Robert Egan
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add to Preferred Sources
Scientists at Rutgers Health have discovered a molecule produced by "good" gut bacteria that rapidly heals the intestinal lining, protecting against severe inflammatory diseases and triggering increased production of a coenzyme whose levels diminish with age.
In tests in mice, flies and human cells, researchers found evidence that the breakthrough molecule—called (amide-)N-methylnicotinamide, or N-MNA—has the potential to treat inflammatory bowel disease and other chronic gut disorders in humans by activating a coenzyme called nicotinamide adenine dinucleotide, or NAD, whose decline is thought to be a major driver of aging.
The study was published in Science Advances.
A bacterial route to replenishing NAD
Tests showed that N-MNA, a precursor molecule, activated NAD, thereby speeding the repair of damaged guts by stimulating stem cell regeneration.
Some species of gut bacteria, including one available in dietary supplements, also produce a precursor of NAD, fueling a market for products meant to bolster it. Because NAD cannot enter cells directly, scientists have been seeking precursors that can be taken up by cells and converted into NAD.
N-MNA is a near twin of a molecule human cells make when they dispose of excess NAD building blocks, but N-MNA, unlike the molecule humans make themselves, can be converted back into NAD.
"Humans do not appear to make this exact precursor molecule N-MNA, but some of the bacteria living in our gut do," said senior study author Nan Gao, a professor of pharmacology, physiology and neuroscience at Rutgers New Jersey Medical School and an expert in fly genetics.
"The molecules animal cells and bacteria make are almost identical, but a tiny difference allows the conversion of the bacterial compound back into NAD itself," said another senior study author, Xiaoyang Su, associate professor of medicine at Rutgers Robert Wood Johnson Medical School. Su is also co-director of the Metabolomics Shared Resource at Rutgers Cancer Institute, New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health.
Gut repair and inflammation signals
Jiangmeng Han, the first author of the study and a doctoral student in biological sciences at Rutgers University-Newark, tracked the molecule into human colon cells, where it supplied about 22% of their NAD within 24 hours. It also became NAD in human neurons, liver cells and kidney cells and in the bodies and heads of fruit flies given it.
In mice with inflamed and damaged colons, untreated animals lost 20% of their body weight and died, while those injected with N-MNA lost 5% and recovered. In fruit flies with damaged guts, N-MNA raised seven-day survival from 43% to 78%.
As for humans, in stool samples from 54 patients with inflammatory bowel disease (IBD) and 20 healthy volunteers, patients with low N-MNA had significantly higher levels of gut inflammation markers.
"Patients with low levels of this metabolite showed a higher inflammatory activity," said Gao.
He added that a stool test might eventually help identify patients likely to benefit from probiotics, though that is probably some years away.
"Right now, we're still trying to understand the fundamentals, and this requires a multidisciplinary team of a biochemist, geneticist and intestinal biologist," Gao said.
Treatment questions remain open
Researchers involved in the study didn't test N-MNA treatment in the IBD patients, nor did they test whether consuming probiotic strains that make N-MNA, including Lactobacilli in yogurt and oral supplements, raises NAD in people.
"This compound itself may be sufficient, but we cannot rule out the possibility that there are other, better compounds," said Ching-On Wong, an assistant professor of biological sciences at Rutgers-Newark and a senior author of the study.
This discovery is a product of cross-unit collaborations among doctoral students and postdoctoral fellows across different Rutgers campuses and departments.
The team will identify the still-unknown human enzymes that process N-MNA. Wong's lab is testing whether the molecule supports brain cell health and longevity, and Gao's lab is mapping the bacterial genes that produce it.
Rutgers has filed a provisional patent application on uses of N-MNA, with Han, Ferraris, Su and Gao named as inventors.
Publication details
Jiangmeng Han et al., The (amide-)N-methylnicotinamide is a microbe-derived NAD + precursor that drives gut stem cell renewal, Science Advances (2026). DOI: 10.1126/sciadv.aef2882
Journal information: Science Advances
Key medical concepts
NADInflammatory Bowel Diseases
Clinical categories
GastroenterologyDigestive healthClinical pharmacologyCommon illnesses & Prevention Provided by Rutgers University Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: A microbe-made molecule may reverse gut damage by boosting NAD levels (2026, November 13) retrieved 13 November 2026 from https://medicalxpress.com/news/2026-11-microbe-molecule-reverse-gut-boosting.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.